Protease inhibitors for treatment of coronavirus infections
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R 1 , R 2 , R 3a , R 3b , R 4 , R 5 , and A are defined in the present disclosure. The compounds are potent inhibitors of the main protease (M pro ) of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), and they are useful in treating or preventing COVID-19 in a subject.
1. A compound, which is (S)-5-((R)-2-hydroxy-4-methylpentanoyl)-N—((S)-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)-4-(trifluoromethoxy)butan-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide, or a pharmaceutically acceptable salt thereof.
2. A compound, which is (S)-5-((R)-2-hydroxy-4-methylpentanoyl)-N—((S)-3-oxo-1-((S)-2-oxopyrrolidin-3-yl)-4-(trifluoromethoxy)butan-2-yl)-5-azaspiro[2.4]heptane-6-carboxamide.
3. A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 1 and a pharmaceutically acceptable carrier.
4. A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.